Cardiovascular and Renal Benefit of Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes

Am J Cardiol. 2024 Jul 15:223:183-185. doi: 10.1016/j.amjcard.2024.05.001. Epub 2024 May 9.
No abstract available

Keywords: cardiovascular outcomes; diabetes; sodium-glucose cotransporter-2 inhibitors (SGLT2i).

Publication types

  • Editorial
  • Comment

MeSH terms

  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / prevention & control
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

  • Sodium-Glucose Transporter 2 Inhibitors
  • Hypoglycemic Agents